false 0001094038 0001094038 2025-01-24 2025-01-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

January 24, 2025

Date of Report (Date of earliest event reported)

 

MARKER THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-37939 45-4497941
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

 

2450 Holcombe Blvd, Suite BCM-A, MS: BCM251

Houston, Texas

   77021
(Address of principal executive offices)   (Zip Code)

 

(713) 400-6400

Registrant’s telephone number, including area code

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange on which registered
Common Stock, par value $0.001 per share   MRKR   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Compensatory Arrangements of Certain Officers.

 

(b)Resignation of Director.

 

On January 24, 2025, Mr. John Wilson resigned from the Board of Directors of Marker Therapeutics, Inc. (the “Company”).

 

Exhibit No. Description 
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Marker Therapeutics, Inc.
     
Dated: January 30, 2025 By: /s/ Juan Vera
    Juan Vera
    President and Chief Executive Officer

 

 

 

v3.24.4
Cover
Jan. 24, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 24, 2025
Entity File Number 001-37939
Entity Registrant Name MARKER THERAPEUTICS, INC.
Entity Central Index Key 0001094038
Entity Tax Identification Number 45-4497941
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2450 Holcombe Blvd
Entity Address, Address Line Two Suite BCM-A
Entity Address, Address Line Three MS: BCM251
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77021
City Area Code 713
Local Phone Number 400-6400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol MRKR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Grafico Azioni Marker Therapeutics (NASDAQ:MRKR)
Storico
Da Gen 2025 a Feb 2025 Clicca qui per i Grafici di Marker Therapeutics
Grafico Azioni Marker Therapeutics (NASDAQ:MRKR)
Storico
Da Feb 2024 a Feb 2025 Clicca qui per i Grafici di Marker Therapeutics